A research team led by Spanish scientist Amelia Escolano, from the Wistar Institute in Philadelphia, has developed a new experimental immunogen, called WIN332, capable of activating a specific immune response against HIV in just a few weeks.

The study, published in Nature Immunology, shows that after two doses administered to rhesus macaques, antibodies capable of neutralizing different strains of the virus are generated.

This breakthrough represents a significant step towards the development of a preventive vaccine that is more effective and faster than the strategies tested to date, although clinical trials in humans will still be necessary to confirm its safety and efficacy.

The trial has successfully activated a specific immune response related to human immunodeficiency virus (HIV) infection after a single dose of the new drug.

Researcher Amelia Escolano leads a research group at the Wistar Institute in Philadelphia, where they design vaccines and immunization strategies to induce antibodies against HIV.

The experiment was conducted using rhesus macaques, which, after receiving a dose of WIN332 immunization, were able to produce antibodies against HIV within three weeks. A second dose further intensified the immune response.

The study proposes a new classification of neutralizing antibodies against HIV. Type I antibodies are dependent on the viral glycan, while type II antibodies are not. WIN332 is the first immunogen designed to induce type II antibodies. These new antibodies target a critical region of the virus known as V3-glycan.

The vaccination protocol involves two doses, and neutralizing activity can be observed three weeks after the first dose. After the second dose, the antibodies are able to neutralize and block different strains of the virus.

Previous HIV vaccine trials required five to ten doses to produce an effective response, with the process lasting months or years, which significantly limited their efficacy. This study therefore represents a major advance in terms of both the effectiveness and speed of the protective effect.

The next step is to find funding to conduct clinical trials of the vaccine in humans.

Background

As we have previously published in our Bioethics Observatory, advances in HIV treatment have come from antiretroviral drugs, which limit the replication of the virus in infected people.

Thus, in 2024 the drug Lenacapavir managed to prevent 100% of AIDS infections in women with a dose of two injections per year.

This new drug for the treatment of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection was approved in 2024 by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).

Lenacapavir, in combination with other antiretroviral drugs, is indicated for the treatment of adults with HIV-1 who cannot be treated with currently available drugs due to resistance, intolerance, or safety considerations.

The results of the trial, conducted on women from South Africa and Uganda, were presented at the 25th International AIDS Conference held in Munich and were published in The New England Journal of Medicine.

During the International AIDS Conference, the case of the seventh patient cured of the disease was also presented. This patient, known as the “second Berlin patient,” had been living with HIV since 2009 and was diagnosed with acute myeloid leukemia in 2015.

As treatment for this disease, she received chemotherapy and a stem cell transplant. The genetic characteristics of the transplanted cells conferred immunity to the infection.

Previously, in 2022, the case of the first woman cured of HIV with umbilical cord stem cells was presented, who was treated for 4 years for the acute myeloid leukemia she suffered from.

In 2009 the “Berlin patient” was the first person in the world to be cured of HIV also thanks to a stem cell transplant.

Prevalence and future perspectives of new therapeutic approaches

According to the UNAIDS report, the prevalence of HIV among adults (aged 15 to 49) was 0.7% worldwide.

Among the risk factors and behaviors that determine the spread of infection are homosexual practices (7.6%), sex workers (2.7%), intravenous drug users (7.1%), transgender people (8.5%), and prisoners (1.4%).

Advances in the treatment of HIV infection have managed to turn into a chronic infection that was fatal for many years after its emergence.

The first advances, thanks to antiretroviral drugs, managed to stop the replication of the virus, making it undetectable in infected patients and preventing its transmission.

Findings related to the case of the “Berlin patient” showed that the perfusion of stem cells with certain genetic characteristics conferred immunity to infection after proliferating in the transplanted individual.

The current finding opens up new therapeutic possibilities in the prevention of HIV infection, potentially offering more effective results than current treatments after human trials.

More importantly, it would come at a lower cost, so its application would be extended to populations that currently do not offer the available treatments.

This is especially relevant in Third World countries where the prevalence is extremely high.

It should be remembered that, according to the UNAIDS report, in 2024, 4,000 adolescents and young women between the ages of 15 and 24 were infected with HIV every week. More than 80% of all cases (3,300) were in sub-Saharan Africa.

However, therapeutic measures should be combined with prophylactic measures, which help to curb the spread of the disease specifically in high-risk groups, as well as the generalization of preventive diagnoses, which should be standardized in primary care.

Julio Tudela and Ester Bosch

Bioethics Observatory – Institute of Life Sciences

Catholic University of Valencia

Share This Story, Choose Your Platform!